NEW GROWTH STRATEGIES FOR BIOPHARMA AND MEDICAL DEVICE

HOW TO COMPETE IN A CHANGING SECTOR?
WHAT OPPORTUNITIES AND CHALLENGES FOR ITALIAN PLAYERS?

CORPORATE & INSTITUTIONAL BANKING

Discussion materials

October 2016

STRICTLY CONFIDENTIAL



Focus on Medtech: Challenges & growth strategies

Medtech is reaching maturity : Outlook more constrained

The slowing pace of innovation will limit top line growth

Cost pressures on broader healthcare system will be increasingly passed along to medical devices

Innovation-driven mix and price opportunities appear more limited

As market volume growth decelerates and healthcare service pressures increase, the industry's historical grip on pricing may slip

Understanding the new environment

Revenue growth rates to consolidate around the low to mid single digits

R&D efficiency will decline

Gross margin expansion is not sustainable

Increase reliance on capital deployment as operational growth matures

Emerging markets become a significant driver of growth

Source: Morgan Stanley Research



So it's med tech finally « safer harbour » than pharma?

- 1 More controlled R&D / pipeline risk, no generic impact for high value added product
- Paster path to market
- However:
 - Big is often better (bundling strategy)
 - Price pressure impacting heavy materials

Italian players: opportunities & challenges

Challenges

- Lower investment in R&D rate compared to other European groups
- Pro capita HC public expenditure lower than European average (-20% for healthcare, -30% for pharma)
- General country ecosystems less "supportive" for early stage R&D financing

Opportunities

- Cutting edge stems cells / gene-therapy expertise
- Historical good positioning in manufacturing (CMO) and complex API production
- Strong engineering academic and country expertise creating attractive global leader in med tech (e.g. Diasorin, Sorin, Esaote)
- Above average international presence offering natural hedge to price cut and reimbursement risk

This presentation has been prepared by BNP PARIBAS for informational purposes only. Although the information contained in this presentation has been obtained from sources which BNP PARIBAS believes to be reliable, it has not been independently verified and no representation or warranty, express or implied, is made and no responsibility is or will be accepted by BNP PARIBAS as to or in relation to the accuracy, reliability or completeness of any such information.

Opinions expressed herein reflect the judgement of BNP PARIBAS as of the date of this presentation and may be subject to change without notice if BNP PARIBAS becomes aware of any information, whether specific or general, which may have a material impact on any such opinions.

BNP PARIBAS will not be responsible for any consequences resulting from the use of this presentation as well as the reliance upon any opinion or statement contained herein or for any omission.

This presentation is confidential and may not be reproduced (in whole or in part) nor summarised or distributed without the prior written permission of BNP PARIBAS.

© BNP PARIBAS. All rights reserved.